Collaboration, License and Option Agreements - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 18, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2019	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Amendment Date				2019-12
Upfront Non-Refundable Payment						$ 20,000,000.0
Revenues		$ 0	$ 300,000	$ 0	$ 300,000
Liability to licensor		19,806,000		$ 19,806,000			$ 19,806,000
BeiGene
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Amendment Date				2020-10
Reimbursement Of Manufacturing Costs						$ 5,000,000.0
Revenues		0	$ 0	$ 0	$ 0
Current portion of deferred revenue	$ 19,800,000	19,800,000		19,800,000			19,800,000
License termination information, Description	In the event the license is terminated, the liability will be extinguished with no further payment to BeiGene.
Liability to licensor		$ 19,800,000		$ 19,800,000			$ 19,800,000